Aoxing Pharmaceutical Company, Inc. announced earnings results for the third quarter and nine month periods ended March 31, 2013. For the quarter, the company reported revenues of $1,885,133, representing a 4% increase over the revenues realized in the comparable periods of fiscal year 2012. The increase in revenue was mainly attributable to the increase in sales of its main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market. Losses from operations were $2,300,366 compared with losses from operations of $436,953 during the same periods a year earlier. Net losses were $2,729,350.

For the nine months, the company reported revenues of $7,804,664, representing a 43% increase over the revenues realized in the comparable periods of fiscal year 2012. The increase in revenue was mainly attributable to the increase in sales of its main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market. Losses from operations were $4,565,272 compared with losses from operations of $1,083,770 during the same periods a year earlier. Net losses were $6,313,526.